<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:department>Brighton and Sussex Medical School</gtr:department><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/004F6989-8A43-4207-A982-11A4FF1F40FC"><gtr:id>004F6989-8A43-4207-A982-11A4FF1F40FC</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>O'Driscoll</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700733"><gtr:id>A02F15F9-A71F-4B8B-A75D-E7BF804A25D3</gtr:id><gtr:title>Understanding at the molecular level the clinical consequences of defective ataxia telangiectasia and Rad3-related (ATR)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700733</gtr:grantReference><gtr:abstractText>Damage to our genetic material, DNA, occurs everyday and if left un-repaired can lead to cell death and/or cancer development. Our DNA can be damaged not only as a result of exposure to genotoxic chemicals or radiation but also indirectly, during normal cellular metabolism. For example, certain enzymes actually introduce breaks at specific locations in our DNA in certain cell types as a normal step during activation of our immune system. This allows the splicing together of distinct pieces of DNA to form new gene combinations to make specific antibodies. Several human genetic disorders exist that are defective in the normal response to DNA damage. One such disorder, Seckel syndrome, can be caused by a mutation in the ataxia telangiectasia and Rad3-related (ATR) gene. This gene creates a protein that functions as a key regulator of the normal response DNA damage. Seckel syndrome is characterised by profound growth retardation, skeletal abnormalities and a dramatically reduced head circumference which denotes a particular brain abnormality called ?microcephaly?. This suggests that the ATR protein plays some fundamental role during skeletal and brain development. What this role is has not been previously determined. This proposal aims to characterise how defective ATR impacts on these processes and results in such a severe condition as Seckel syndrome.</gtr:abstractText><gtr:technicalSummary>The importance of a functional DNA damage response is underscored by the growing list of human congenital disorders associated with defective DNA repair/damage responses. Whilst such disorders frequently exhibit genomic instability and consequent tumour predisposition, additional clinical features suggest a role of a functional DNA damage response in normal human development. Ataxia telangiectasia and Rad3-related (ATR) protein plays a pivotal signalling role in effecting the normal response to DNA damage. Mutations in ATR result in Seckel syndrome. This condition is characterised by severe microcephaly (reduced brain size), profound growth delay, and specific skeletal abnormalities. Interestingly, other DNA damage response disorders that are clinically similar to Seckel syndrome also exhibit defects in ATR pathway function (eg. Nijmegen breakage syndrome, Fanconi anaemia, Microcephalin associated primary microcephaly). This suggests that the ATR pathway plays a specific, fundamental, although as yet undefined role in the normal development of the brain and skeletal system. This proposal aims to define and characterise the role of ATR in these processes.</gtr:technicalSummary><gtr:fund><gtr:end>2011-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>320249</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Visit to our Institue</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>60A7518B-EBD4-42C0-A8B8-36A8FC0A591D</gtr:id><gtr:impact>On average 25 people attend a presentation and tour of our institute. This involved formal presentation (in laymans terms), informal guided tour of the labs and facilities followed by a Q&amp;amp;A session.

Many participants have asked to return again in the furture for another tour.</gtr:impact><gtr:outcomeId>nKCaQy36V5w</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit to Eastbourne (Royal Hotel) for CR-UK Legacy Team presentation as a funded scientist</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C9436A60-F11D-4905-BACA-3B85DC18CDB3</gtr:id><gtr:impact>Presentation to a lay audience (including Q&amp;amp;A) about cancer, genomic stability and the work being conduted at the GDSC in Sussex.

I have been asked to present again in a similar format.</gtr:impact><gtr:outcomeId>jLkC7ALKm73</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>146000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Lymphoma Research Project Grant</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>90658D67-430C-44AD-99F9-B8D069B4533D</gtr:id><gtr:outcomeId>k6j6ef7d7Hj0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Contributed to and was acknowledged in CR-UK policy document &amp;quot;Building the ideal enviornment for medical research&amp;quot;.</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F938F897-64FC-4B0E-8A46-82ADD09C0EE5</gtr:id><gtr:outcomeId>LfTg5fM4hKs</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C977BB36-B144-417F-BA13-6253AD60C6EA</gtr:id><gtr:title>Encyclopedia of Life Sciences</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36becaa53198c21b97c7bcd0597bf726"><gtr:id>36becaa53198c21b97c7bcd0597bf726</gtr:id><gtr:otherNames>Lehmann A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2001-01-01</gtr:date><gtr:isbn>0470016175</gtr:isbn><gtr:outcomeId>mvwaaRvPovo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E79AF07-7F46-4A9B-B835-165A14449641</gtr:id><gtr:title>CUL4B-deficiency in humans: understanding the clinical consequences of impaired Cullin 4-RING E3 ubiquitin ligase function.</gtr:title><gtr:parentPublicationTitle>Mechanisms of ageing and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b38439713ea15aed05ba5c9b8b12ab7"><gtr:id>2b38439713ea15aed05ba5c9b8b12ab7</gtr:id><gtr:otherNames>Kerzendorfer C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0047-6374</gtr:issn><gtr:outcomeId>SeMVedE6WKn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11CCEE81-DFD5-43CD-9F3F-FBED1D893BED</gtr:id><gtr:title>Life can be stressful without ATR.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e3bc4365e829c93498893e2f2dbeab5"><gtr:id>6e3bc4365e829c93498893e2f2dbeab5</gtr:id><gtr:otherNames>O'Driscoll M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>17B0BD247A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAD49C86-FA3B-4760-97FB-53384525D696</gtr:id><gtr:title>Early Diagnosis of Werner's Syndrome Using Exome-Wide Sequencing in a Single, Atypical Patient.</gtr:title><gtr:parentPublicationTitle>Frontiers in endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d27fbf1e66662650d0cc46de3f20ec4"><gtr:id>9d27fbf1e66662650d0cc46de3f20ec4</gtr:id><gtr:otherNames>Raffan E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1664-2392</gtr:issn><gtr:outcomeId>EjFa3UZMox2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49EB5090-22E9-4C5C-978D-C6FAA35370C8</gtr:id><gtr:title>Mouse models for ATR deficiency.</gtr:title><gtr:parentPublicationTitle>DNA repair</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e3bc4365e829c93498893e2f2dbeab5"><gtr:id>6e3bc4365e829c93498893e2f2dbeab5</gtr:id><gtr:otherNames>O'Driscoll M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1568-7856</gtr:issn><gtr:outcomeId>505BA0519C1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2636ADEB-DDE8-403E-B2E2-79F5B5AC1F6E</gtr:id><gtr:title>Replication independent ATR signalling leads to G2/M arrest requiring Nbs1, 53BP1 and MDC1.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61c3688af3a17a1d0b4b1db0765c0536"><gtr:id>61c3688af3a17a1d0b4b1db0765c0536</gtr:id><gtr:otherNames>Stiff T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>B32E69C73EF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A0A5D80-9B44-4395-A43F-EC8115586CC4</gtr:id><gtr:title>The consequences of structural genomic alterations in humans: genomic disorders, genomic instability and cancer.</gtr:title><gtr:parentPublicationTitle>Seminars in cell &amp; developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/936b495fb9e9df83904cc648f80a901e"><gtr:id>936b495fb9e9df83904cc648f80a901e</gtr:id><gtr:otherNames>Colnaghi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1084-9521</gtr:issn><gtr:outcomeId>aQ7geVmSnbW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFDB8890-0459-475A-B94A-57B4F62525E0</gtr:id><gtr:title>Primary Immunodeficiency Diseases - A Molecular and Genetic Approach</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e3bc4365e829c93498893e2f2dbeab5"><gtr:id>6e3bc4365e829c93498893e2f2dbeab5</gtr:id><gtr:otherNames>O'Driscoll M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>9780195389838</gtr:isbn><gtr:outcomeId>gSJkKYZLvzB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECA988CA-A8A6-410A-9389-BA456ED1D3BA</gtr:id><gtr:title>Neuropathology of fetal stage Seckel syndrome: a case report providing a morphological correlate for the emerging molecular mechanisms.</gtr:title><gtr:parentPublicationTitle>Brain &amp; development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbc9cf6834de8f2144ff25456fdc3885"><gtr:id>cbc9cf6834de8f2144ff25456fdc3885</gtr:id><gtr:otherNames>Fitzgerald B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0387-7604</gtr:issn><gtr:outcomeId>eutHbWhR2Zq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5313DB24-89E4-4194-9301-F9820F321892</gtr:id><gtr:title>Increased RPA1 gene dosage affects genomic stability potentially contributing to 17p13.3 duplication syndrome.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89b4e75443c0bebc5b526d43023b4267"><gtr:id>89b4e75443c0bebc5b526d43023b4267</gtr:id><gtr:otherNames>Outwin E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>HWhyvkkdvuY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DE40610-9D6C-45FA-B572-974F18CA8243</gtr:id><gtr:title>Genetic defects in human pericentrin are associated with severe insulin resistance and diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/120893d6db842ae2fac96265727b0fb4"><gtr:id>120893d6db842ae2fac96265727b0fb4</gtr:id><gtr:otherNames>Huang-Doran I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>WUhBXoLeLxW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAE718BA-BD1F-41CC-8CD6-E3D047667011</gtr:id><gtr:title>Understanding the impact of 1q21.1 copy number variant.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf4777e77695aff106a337dd5d0957c8"><gtr:id>bf4777e77695aff106a337dd5d0957c8</gtr:id><gtr:otherNames>Harvard C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>VUGWM519a9D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A6E47E3-C9FD-4CFD-B5C3-43A6DAFEB0B2</gtr:id><gtr:title>UVB and caffeine: inhibiting the DNA damage response to protect against the adverse effects of UVB.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b38439713ea15aed05ba5c9b8b12ab7"><gtr:id>2b38439713ea15aed05ba5c9b8b12ab7</gtr:id><gtr:otherNames>Kerzendorfer C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>8E6EE14BE67</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F7B93AF-3C47-4BEA-9B11-8861D04BE70C</gtr:id><gtr:title>Mutations in ORC1, encoding the largest subunit of the origin recognition complex, cause microcephalic primordial dwarfism resembling Meier-Gorlin syndrome.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/440979fc6fdb7b7460900c4dd8acd2e4"><gtr:id>440979fc6fdb7b7460900c4dd8acd2e4</gtr:id><gtr:otherNames>Bicknell LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>K7cBB28a9Rj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEA7AC60-409E-44E6-88B9-3664143D2D58</gtr:id><gtr:title>Haploinsufficiency of DNA Damage Response Genes and their Potential Influence in Human Genomic Disorders.</gtr:title><gtr:parentPublicationTitle>Current genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e3bc4365e829c93498893e2f2dbeab5"><gtr:id>6e3bc4365e829c93498893e2f2dbeab5</gtr:id><gtr:otherNames>O'Driscoll M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1389-2029</gtr:issn><gtr:outcomeId>67E9DF19B00</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4065EB1E-427F-4741-AF5B-311872D87CED</gtr:id><gtr:title>Mutations in Cullin 4B result in a human syndrome associated with increased camptothecin-induced topoisomerase I-dependent DNA breaks.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b38439713ea15aed05ba5c9b8b12ab7"><gtr:id>2b38439713ea15aed05ba5c9b8b12ab7</gtr:id><gtr:otherNames>Kerzendorfer C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>AhBTMW7QqDT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64625C6C-7E12-4783-9848-1A3D9C8F39E0</gtr:id><gtr:title>Human DNA damage response and repair deficiency syndromes: linking genomic instability and cell cycle checkpoint proficiency.</gtr:title><gtr:parentPublicationTitle>DNA repair</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b38439713ea15aed05ba5c9b8b12ab7"><gtr:id>2b38439713ea15aed05ba5c9b8b12ab7</gtr:id><gtr:otherNames>Kerzendorfer C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1568-7856</gtr:issn><gtr:outcomeId>1C031E7E00D</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700733</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>78FE8F42-8AFB-48F8-8662-37D541AD95BF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Congenital Disorders</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>